Download PDF
CC BY 4.0 · World J Nucl Med 2023; 22(01): 036-039
DOI: 10.1055/s-0042-1757254
Case Report

An Uncommon Presentation of Leptomeningeal Metastases in Breast Carcinoma Detected by F-18 FDG PET/CT

Gavini Surya
1   Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
,
Nimmagadda Ajit
1   Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
,
Rallapeta Ramya Priya
1   Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
,
Dhamarcherla S. Hemalatha
1   Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
,
Bodagala Vijayalakshmi Devi
2   Department of Radiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
,
Tekchand Kalawat
1   Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Leptomeningeal carcinomatosis is a manifestation in which tumor cells migrate into meninges. Breast carcinoma presenting with leptomeningeal metastases is a rare phenomenon that can occur in an isolated form as well as with coexistent parenchymal brain metastases. The gold standard for diagnosis is cerebrospinal fluid analysis, while contrast-enhanced magnetic resonance imaging is the most commonly used imaging modality. Nuclear medicine imaging with flourine-18-fluorodeoxyglucose positron emission tomography/computed tomography has proved to be useful in detecting leptomeningeal metastases and, at times, even before anatomical changes occur. Here, we present a case of breast carcinoma presenting with both pachymeningeal and leptomeningeal metastases 10 years after treatment.

Keywords

breast cancer - F-18 FDG PET/CT - leptomeningeal metastases


Publication History

Article published online:
09 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Pellerino A, Brastianos PK, Rudà R, Soffietti R. Leptomeningeal metastases from solid tumors: recent advances in diagnosis and molecular approaches. Cancers (Basel) 2021; 13 (12) 2888
    CrossrefPubMedGoogle Scholar
  • 2 Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49 (04) 759-772
    CrossrefPubMedGoogle Scholar
  • 3 Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013; 4 (4, Suppl 4): S265-S288
    CrossrefPubMedGoogle Scholar
  • 4 Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol 2013; 30 (01) 408
    CrossrefPubMedGoogle Scholar
  • 5 Corso G, Pravettoni G, Galimberti V, Veronesi P. Clinical implication of E-cadherin deficiency in lobular breast cancer. Breast Cancer Res Treat 2019; 173 (03) 751-752
    CrossrefPubMedGoogle Scholar
  • 6 Yust-Katz S, Garciarena P, Liu D. et al. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol 2013; 114 (02) 229-235
    CrossrefPubMedGoogle Scholar
  • 7 Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996; 53 (07) 626-632
    CrossrefPubMedGoogle Scholar
  • 8 Glantz MJ, Cole BF, Glantz LK. et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82 (04) 733-739
    CrossrefPubMedGoogle Scholar
  • 9 Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999; 246 (09) 810-814
    CrossrefPubMedGoogle Scholar
  • 10 Nayar G, Ejikeme T, Chongsathidkiet P. et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 2017; 8 (42) 73312-73328
    CrossrefPubMedGoogle Scholar
  • 11 Mason WP, Yeh SD, DeAngelis LM. 111Indium-DTPA cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998; 50 (02) 438-444
    CrossrefPubMedGoogle Scholar
  • 12 Intriago B, Danús M, Añaños M, Trampal C, Montero M, Calvo N. 18F-FDG PET detection of spinal leptomeningeal metastases from cerebral glioblastoma multiforme. Eur J Nucl Med Mol Imaging 2011; 38 (07) 1392
    CrossrefPubMedGoogle Scholar
  • 13 Ortapamuk H, Demir MK. Intracranial leptomeningeal carcinomatosis in three cases from breast cancer demonstrated on F-18 fluorodeoxyglucose positron emission tomography/computerized tomography. Indian J Nucl Med 2017; 32 (01) 16-18
    CrossrefPubMedGoogle Scholar
  • 14 Short RG, Bal S, German JP, Poelstra RJ, Kardan A. Potential of F-18 PET/CT in the detection of leptomeningeal metastasis. Neuroradiol J 2014; 27 (06) 685-689
    CrossrefPubMedGoogle Scholar
  • 15 Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol 2019; 135: 85-94
    CrossrefPubMedGoogle Scholar
  • 16 Morikawa A, Jordan L, Rozner R. et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer 2017; 17 (01) 23-28
    CrossrefPubMedGoogle Scholar